Premier, Inc. Reports Fiscal-Year 2025 Fourth-Quarter and Full-Year Financial Results
-
Fourth-quarter total net revenue of
$262.9 million $258.0 million -
Fourth-quarter GAAP net income from continuing operations of
$18.0 million $0.22 -
Fourth-quarter adjusted EPS of
$0.46 -
Full-year net cash provided by operating activities from continuing operations of
$417.8 million $180.5 million - Providing fiscal-year 2026 financial guidance
Fiscal-year 2025 fourth quarter total net revenue of
"I'm pleased to report that we had a strong finish to the year despite the contract renewal headwinds, which are now mostly behind us. Our overall revenue and profitability for the year exceeded our expectations largely due to better-than-anticipated results in our Supply Chain Services segment," said Michael J. Alkire, Premier's President and CEO. "In addition, we continued to return meaningful capital to stockholders through our quarterly cash dividend and the completion of a
On October 1, 2024, the company announced that it had divested the S2S Global direct sourcing business. As such, and unless stated otherwise, all results presented in the following release reflect those of continuing operations. In addition, as the company's efforts to transfer to partners or wind down certain components of the Contigo Health business remain ongoing, results presented in this release continue to include contributions from that business. However, because of the expected transition and/or wind-down, the company is providing certain financial measures that exclude contributions from this business, and tables are included at the end of this release that reconcile the impact of the Contigo Health business on certain financial measures in the periods presented.
Consolidated Financial Highlights of Continuing Operations |
|||||||||||||
|
Three Months Ended June 30, |
|
Year Ended June 30, |
||||||||||
(in thousands, except per share data) |
2025 |
2024 |
% Change |
|
2025 |
2024 |
% Change |
||||||
Net revenue: |
|
|
|
|
|
|
|
||||||
Supply Chain Services: |
|
|
|
|
|
|
|
||||||
Net administrative fees |
$ |
150,052 |
$ |
166,146 |
(10 |
%) |
|
$ |
556,328 |
$ |
624,168 |
(11 |
%) |
Software licenses, other services and support |
|
19,948 |
|
18,262 |
9 |
% |
|
|
74,711 |
|
65,200 |
15 |
% |
Total Supply Chain Services |
|
170,000 |
|
184,408 |
(8 |
%) |
|
|
631,039 |
|
689,368 |
(8 |
%) |
Performance Services |
|
92,857 |
|
115,838 |
(20 |
%) |
|
|
381,608 |
|
446,641 |
(15 |
%) |
Performance Services excluding Contigo Health |
|
87,972 |
|
107,253 |
(18 |
%) |
|
|
354,914 |
|
406,795 |
(13 |
%) |
Net revenue |
$ |
262,857 |
$ |
300,246 |
(12 |
%) |
|
$ |
1,012,647 |
$ |
1,136,009 |
(11 |
%) |
Net revenue excluding Contigo Health* |
$ |
257,972 |
$ |
291,661 |
(12 |
%) |
|
$ |
985,953 |
$ |
1,096,163 |
(10 |
%) |
|
|
|
|
|
|
|
|
||||||
Net income from continuing operations |
$ |
18,018 |
$ |
60,861 |
(70 |
%) |
|
$ |
72,734 |
$ |
104,219 |
(30 |
%) |
Net income from continuing operations attributable to stockholders |
$ |
18,572 |
$ |
60,932 |
(70 |
%) |
|
$ |
62,170 |
$ |
117,044 |
(47 |
%) |
Diluted earnings per share from continuing operations attributable to stockholders |
$ |
0.22 |
$ |
0.57 |
(61 |
%) |
|
$ |
0.68 |
$ |
1.02 |
(33 |
%) |
Consolidated Non-GAAP Financial Highlights of Continuing Operations* |
|||||||||||||||||
|
Three Months Ended June 30, |
|
Year Ended June 30, |
||||||||||||||
(in thousands, except per share data) |
|
2025 |
|
|
2024 |
|
% Change |
|
|
2025 |
|
|
2024 |
|
% Change |
||
Adjusted EBITDA: |
|
|
|
|
|
|
|
||||||||||
Supply Chain Services |
$ |
89,986 |
|
$ |
109,617 |
|
(18 |
%) |
|
$ |
326,902 |
|
$ |
409,669 |
|
(20 |
%) |
Performance Services |
|
17,170 |
|
|
32,820 |
|
(48 |
%) |
|
|
60,692 |
|
|
113,845 |
|
(47 |
%) |
Total segment adjusted EBITDA |
|
107,156 |
|
|
142,437 |
|
(25 |
%) |
|
|
387,594 |
|
|
523,514 |
|
(26 |
%) |
Corporate |
|
(38,300 |
) |
|
(38,424 |
) |
— |
% |
|
|
(134,474 |
) |
|
(134,529 |
) |
— |
% |
Adjusted EBITDA |
$ |
68,856 |
|
$ |
104,013 |
|
(34 |
%) |
|
$ |
253,120 |
|
$ |
388,985 |
|
(35 |
%) |
Adjusted EBITDA excluding Contigo Health |
$ |
71,108 |
|
$ |
106,045 |
|
(33 |
%) |
|
$ |
260,435 |
|
$ |
396,191 |
|
(34 |
%) |
Adjusted net income |
$ |
35,743 |
|
$ |
64,482 |
|
(45 |
%) |
|
$ |
133,752 |
|
$ |
237,846 |
|
(44 |
%) |
Adjusted EPS |
$ |
0.43 |
|
$ |
0.61 |
|
(30 |
%) |
|
$ |
1.46 |
|
$ |
2.08 |
|
(30 |
%) |
Adjusted EPS excluding Contigo Health |
$ |
0.46 |
|
$ |
0.64 |
|
(28 |
%) |
|
$ |
1.54 |
|
$ |
2.17 |
|
(29 |
%) |
* These are non-GAAP financial measures. Refer to "Premier's Use and Definitions of Non-GAAP Measures" below and the supplemental financial information at the end of this release for information on the company's use of non-GAAP measures and a reconciliation of reported GAAP results to non-GAAP results. |
Fiscal-Year 2026 Guidance
Certain statements in this release, including without limitation, those in this section, are forward-looking statements. For additional information regarding the use and limitations of such statements, refer to "Cautionary Note Regarding Forward-Looking Statements" below.
Based on its current outlook and the realization of the assumptions outlined below, the company expects the following:
Guidance Metric |
Fiscal-Year 2026 Guidance Range [1] [2] (as of August 19, 2025) |
Segment Net Revenue: |
|
Supply Chain Services |
|
Performance Services Excluding Contigo Health |
|
Total Net Revenue Excluding Contigo Health |
|
Adjusted EBITDA |
|
Adjusted Net Income |
|
Adjusted EPS |
|
Diluted Weighted Average Shares |
81 million to 83 million |
Fiscal-year 2026 guidance is based on the realization of the following key assumptions:
|
|
| [1] | Adjusted EBITDA, adjusted net income, adjusted EPS and free cash flow presented in this financial guidance are forward-looking non-GAAP measures. Refer to "Premier's Use and Definitions of Non-GAAP Measures" below for information on the company's use of non-GAAP measures. The company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. Total Net Revenue Excluding Contigo Health is also a forward-looking non-GAAP measure. Refer to "Premier's Use of Forward-Looking Non-GAAP Measures" below for additional explanation. |
[2] |
As a result of the company's expectation that the remaining operations of Contigo Health will be substantially, if not entirely, transitioned to partners or wound down by December 31, 2025, guidance is being presented excluding financial contributions from this business. |
Results of Operations for the Three Months Ended June 30, 2025
(As compared with the three months ended June 30, 2024)
GAAP net revenue of
GAAP net income from continuing operations of
GAAP diluted EPS from continuing operations of
Adjusted EBITDA of
Adjusted net income of
Segment Results
(For the fiscal fourth quarter of 2025 as compared with the fiscal fourth quarter of 2024)
Supply Chain Services
Supply Chain Services segment net revenue of
Net administrative fees revenue of
Software licenses, other services and support revenue of
Segment adjusted EBITDA of
Performance Services
Performance Services segment net revenue of
Segment adjusted EBITDA of
Liquidity and Cash Flows
As of June 30, 2025, cash and cash equivalents were
Net cash provided by operating activities from continuing operations ("operating cash flow") for the year ended June 30, 2025 of
Net cash used in investing activities for the year ended June 30, 2025 of
Net cash used in financing activities for the year ended June 30, 2025 of
Non-GAAP free cash flow for the year ended June 30, 2025 was
Return of Capital to Stockholders
In February 2024, the company announced that its Board of Directors ("Board") approved the Share Repurchase Authorization. Pursuant to the Share Repurchase Authorization, which expired on June 30, 2025, the company has repurchased an aggregate of
During fiscal-year 2025, the company paid aggregate dividends of
Conference Call and Webcast
Premier will host a conference call to provide additional detail around the company's performance and outlook today at 8:00 a.m. ET. The call will be webcast live from the company's website and, along with the accompanying presentation, will be available at the following link to the company's Events and Presentations page at https://investors.premierinc.com/overview/default.aspx: Premier Events. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company's website under Events and Presentations at https://investors.premierinc.com/overview/default.aspx.
For those parties who do not have internet access, the conference call may be accessed by calling one of the below telephone numbers and asking to join the Premier, Inc. call:
Domestic participant dial-in number (toll-free): |
(833) 953-2438 |
International participant dial-in number: |
(412) 317-5767 |
About Premier, Inc.
Premier, Inc. (NASDAQ: PINC) is a leading technology-driven healthcare improvement company, providing solutions to two-thirds of all healthcare providers in the
Premier’s Use and Definitions of Non-GAAP Measures
Premier uses EBITDA, adjusted EBITDA, segment adjusted EBITDA, adjusted net income, adjusted earnings per share, and free cash flow. These are non-GAAP financial measures that are not in accordance with, or an alternative to, GAAP, and may be different from non-GAAP financial measures used by other companies. We include these non-GAAP financial measures to facilitate a comparison of the company’s operating performance on a consistent basis from period to period and to provide measures that, when viewed in combination with its results prepared in accordance with GAAP, we believe allow for a more complete understanding of factors and trends affecting the company’s business than GAAP measures alone.
Management believes EBITDA, adjusted EBITDA and segment adjusted EBITDA assist the company’s board of directors, management and investors in comparing the company’s operating performance on a consistent basis from period to period by removing the impact of the company’s earnings elements attributable to the company's asset base (primarily depreciation and amortization), certain items outside the control of management, e.g., taxes, other non-cash items (such as impairment of intangible assets, purchase accounting adjustments and stock-based compensation), non-recurring items (such as strategic initiative and restructuring-related expenses) and income and expense that have been classified as discontinued operations from operating results.
Management believes adjusted net income and adjusted earnings per share assist the company's board of directors, management and investors in comparing our net income and earnings per share on a consistent basis from period to period because these measures remove non-cash items (such as impairment of intangible assets, purchase accounting adjustments and stock-based compensation) and non-recurring items (such as strategic initiative and restructuring-related expenses) and eliminate the variability of non-controlling interest and equity in net income of unconsolidated affiliates.
Management believes free cash flow is an important measure because it represents the cash that the company generates after payments to certain former limited partners that elected to execute a Unit Exchange and Tax Receivable Agreement (“Unit Exchange Agreement") in connection with our August 2020 restructuring, capital investment to maintain existing products and services and ongoing business operations, as well as development of new and upgraded products and services to support future growth and cash payments to OMNIA for the sale of future revenues and tax payments on proceeds received from the sale of future revenues. Free cash flow is important because it enables the company to seek enhancement of stockholder value through acquisitions, partnerships, joint ventures, investments in related or complementary businesses and/or debt reduction.
Also, adjusted EBITDA and free cash flow are supplemental financial measures used by the company and by external users of our financial statements and are considered to be indicators of the operational strength and performance of our business. Adjusted EBITDA and free cash flow measures allow us to assess our performance without regard to financing methods and capital structure and without the impact of other matters that we do not consider indicative of the operating performance of our business. More specifically, segment adjusted EBITDA is the primary earnings measure we use to evaluate the performance of our business segments.
Non-recurring items are income or expenses and other items that have not been earned or incurred within the prior two years and are not expected to recur within the next two years. Such items include acquisition- and disposition-related expenses, strategic initiative- and restructuring-related expenses, loss on disposal of long-lived assets, income and expense that has been classified as discontinued operations and other reconciling items.
Non-cash items include stock-based compensation expense and asset impairments.
Non-operating items include gains or losses on the disposal of assets, interest and investment income or expense, equity in net income of unconsolidated affiliates and operating income from revenues sold to OMNIA in connection with the sale of non-healthcare GPO member contracts, less royalty payments retained.
EBITDA is defined as net income before income or loss from discontinued operations, net of tax, interest and investment income or expense, net, income tax expense, depreciation and amortization and amortization of purchased intangible assets.
Adjusted EBITDA is defined as EBITDA before merger and acquisition-related expenses and non-recurring, non-cash or non-operating items.
Segment adjusted EBITDA is defined as the segment’s net revenue less cost of revenue and operating expenses directly attributable to the segment excluding depreciation and amortization, amortization of purchased intangible assets, merger and acquisition-related expenses and non-recurring or non-cash items. Operating expenses directly attributable to the segment include expenses associated with sales and marketing, general and administrative, and product development activities specific to the operation of each segment. General and administrative corporate expenses that are not specific to a particular segment are not included in the calculation of segment adjusted EBITDA. Segment adjusted EBITDA also excludes any income and expense that has been classified as discontinued operations and operating income from revenues sold to OMNIA in connection with the sale of non-healthcare GPO member contracts, less royalty payments retained.
Adjusted net income is defined as net income attributable to Premier (i) excluding income or loss from discontinued operations, net, (ii) excluding income tax expense, (iii) excluding the effect of non-recurring or non-cash items, including certain strategic initiative- and restructuring-related expenses, (iv) reflecting an adjustment for income tax expense on Non-GAAP net income before income taxes at our estimated annual effective income tax rate, adjusted for unusual or infrequent items, (v) excluding the equity in net income of unconsolidated affiliates and (vi) excluding operating income from revenues sold to OMNIA in connection with the sale of non-healthcare GPO member contracts, less royalty fees retained, imputed interest expense and associated income tax expense.
Adjusted earnings per share is adjusted net income divided by diluted weighted average shares.
Free cash flow is defined as net cash provided by operating activities from continuing operations less (i) early termination payments to certain former limited partners that elected to execute a Unit Exchange Agreement in connection with our August 2020 restructuring, (ii) purchases of property and equipment and (iii) cash payments to OMNIA for the sale of future revenues and tax payments on proceeds received from the sale of future revenues. Free cash flow does not represent discretionary cash available for spending as it excludes certain contractual obligations such as debt repayments.
To properly and prudently evaluate our business, readers are urged to review the reconciliation of these non-GAAP financial measures, as well as the other financial tables, included at the end of this release. Readers should not rely on any single financial measure to evaluate the company’s business. In addition, the non-GAAP financial measures used in this release are susceptible to varying calculations and may differ from, and may therefore not be comparable to, similarly titled measures used by other companies.
The Company has revised the definitions for adjusted EBITDA, segment adjusted EBITDA, adjusted net income and free cash flow from the definitions reported in the 2024 Annual Report. Adjusted EBITDA and segment adjusted EBITDA definitions were revised to exclude operating income from revenues sold to OMNIA in connection with the sale of non-healthcare GPO member contracts, less royalty fees retained. The adjusted net income definition was revised to exclude operating income from revenues sold to OMNIA in connection with the sale of non-healthcare GPO member contracts, less royalty fees retained, imputed interest expense and associated income tax expense. Free cash flow was revised to exclude the cash payments to OMNIA for the sale of future revenues and tax payments on proceeds received from the sale of future revenues. For comparability purposes, prior year non-GAAP financial measures are presented based on the current definitions in the above section.
In addition to the foregoing, this release and the reconciliations of our non-GAAP financial measures included at the end of this release include the presentation of additional fiscal-year 2025 non-GAAP financial measures including net revenue excluding Contigo Health, adjusted EBITDA excluding Contigo Health and adjusted earnings per share excluding Contigo Health. As the company continues to own and operate Contigo Health's remaining businesses, GAAP financial results presented in this release include contributions from these remaining businesses. The company expects that these remaining businesses will be substantially, if not entirely, transitioned to partners or wound down by December 31, 2025. Given the time span that has been required to effectuate the disposition and wind-down of Contigo Health, the company currently does not expect that it will qualify to treat this business as a discontinued operation in fiscal-year 2025. However, because of the expected transition and/or wind-down, guidance presented in this release excludes financial contributions from these remaining businesses. Accordingly, we believe that providing supplemental non-GAAP financial measures that align with our fiscal-year 2025 guidance allow for a better understanding of that guidance.
Further information on Premier’s use of non-GAAP financial measures is available in the “Our Use of Non-GAAP Financial Measures” section of Premier’s Form 10-K for the year ended June 30, 2025, expected to be filed with the SEC shortly after this release, and which will also be made available on Premier's website at investors.premierinc.com.
Premier's Use of Forward-Looking Non-GAAP Measures
The company does not meaningfully reconcile guidance for non-GAAP adjusted EBITDA, non-GAAP adjusted net income and non-GAAP adjusted earnings per share to net income attributable to stockholders or earnings per share attributable to stockholders (and accordingly does not meaningfully reconcile free cash flow guidance, which is based on adjusted EBITDA) because the company cannot provide guidance for the more significant reconciling items between net income attributable to stockholders and each of these metrics without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, which may include, without limitation, items included in the supplemental financial information for reconciliation of reported GAAP results to non-GAAP results. Such items include, but are not limited to, strategic and acquisition related expenses for professional fees; mark to market adjustments for put options and contingent liabilities; gains and losses on stock-based performance shares; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the company believes to be non-indicative of its ongoing operations. Such adjustments may be affected by changes in ongoing assumptions, judgements, as well as non-recurring, unusual or unanticipated charges, expenses or gains/losses or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments is not currently determinable but may be significant.
As noted above, as a result of the company's expectation that the remaining businesses of Contigo Health will be substantially, if not entirely, transitioned to partners or wound down by December 31, 2025, the forward-looking guidance presented in this release (including Total Net Revenue Excluding Contigo Health, adjusted EBITDA, adjusted net income, adjusted EPS and free cash flow), excludes the financial contributions from these remaining businesses, in addition to any applicable adjustments for non-GAAP financial measures described above under "Premier's Use and Definitions of Non-GAAP Measures." With respect to these adjustments for Contigo Health, the company does not meaningfully reconcile guidance to GAAP measures because Contigo Health is expected to be transitioned to partners or wound down.
Cautionary Note Regarding Forward-Looking Statements
Statements made in this release that are not statements of historical or current facts, including, but not limited to, those related to our ability to advance our business strategies and improve healthcare, our ability to transition to partners or wind down the remaining operations of Contigo Health and the potential costs and expenses associated therewith, the potential benefits of share repurchases made pursuant to the share repurchase authorization approved by our Board in 2024 (including the recently completed 2025 ASR), the payment of dividends at current levels or at all, guidance on expected future financial performance and assumptions underlying that guidance, and our expected effective income tax rate, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Premier to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements, the achievement of which cannot be guaranteed. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Premier’s beliefs and expectations regarding future events and trends affecting its business and are necessarily subject to risks and uncertainties, many of which are outside Premier’s control. More information on risks and uncertainties that could affect Premier’s business, achievements, performance, financial condition and financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Premier’s periodic and current filings with the SEC, including the information in those sections of Premier’s Form 10-K for the year ended June 30, 2025, expected to be filed with the SEC shortly after the date of this release. Premier's periodic and current filings with the SEC are made available on Premier’s website at investors.premierinc.com. Forward-looking statements speak only as of the date they are made, and Premier undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events that occur after that date, or otherwise.
Consolidated Statements of Income |
|||||||||||||
(In thousands, except per share data) |
|||||||||||||
|
|
|
|
|
|
||||||||
|
Three Months Ended |
|
Year Ended |
||||||||||
|
June 30, |
|
June 30, |
||||||||||
|
|
2025 |
|
|
2024 |
|
|
|
2025 |
|
|
2024 |
|
Net revenue: |
|
|
|
|
|
||||||||
Net administrative fees |
$ |
150,052 |
|
$ |
166,146 |
|
|
$ |
556,328 |
|
$ |
624,168 |
|
Software licenses, other services and support |
|
112,805 |
|
|
134,100 |
|
|
|
456,319 |
|
|
511,841 |
|
Net revenue |
|
262,857 |
|
|
300,246 |
|
|
|
1,012,647 |
|
|
1,136,009 |
|
Cost of revenue: |
|
|
|
|
|
||||||||
Services and software licenses |
|
64,293 |
|
|
68,427 |
|
|
|
269,288 |
|
|
268,885 |
|
Cost of revenue |
|
64,293 |
|
|
68,427 |
|
|
|
269,288 |
|
|
268,885 |
|
Gross profit |
|
198,564 |
|
|
231,819 |
|
|
|
743,359 |
|
|
867,124 |
|
Operating expenses: |
|
|
|
|
|
||||||||
Selling, general, and administrative |
|
163,512 |
|
|
138,381 |
|
|
|
701,420 |
|
|
690,337 |
|
Research and development |
|
689 |
|
|
663 |
|
|
|
2,634 |
|
|
3,115 |
|
Amortization of purchased intangible assets |
|
9,499 |
|
|
9,794 |
|
|
|
38,189 |
|
|
47,026 |
|
Operating expenses |
|
173,700 |
|
|
148,838 |
|
|
|
742,243 |
|
|
740,478 |
|
Operating income |
|
24,864 |
|
|
82,981 |
|
|
|
1,116 |
|
|
126,646 |
|
Equity in net income (loss) of unconsolidated affiliates |
|
123 |
|
|
1,344 |
|
|
|
11,972 |
|
|
(295 |
) |
Interest expense, net |
|
(6,305 |
) |
|
(73 |
) |
|
|
(17,223 |
) |
|
(662 |
) |
Other income, net |
|
6,419 |
|
|
2,332 |
|
|
|
102,184 |
|
|
20,832 |
|
Other income, net |
|
237 |
|
|
3,603 |
|
|
|
96,933 |
|
|
19,875 |
|
Income before income taxes |
|
25,101 |
|
|
86,584 |
|
|
|
98,049 |
|
|
146,521 |
|
Income tax expense |
|
7,083 |
|
|
25,723 |
|
|
|
25,315 |
|
|
42,302 |
|
Net income from continuing operations |
|
18,018 |
|
|
60,861 |
|
|
|
72,734 |
|
|
104,219 |
|
Net (loss) income from discontinued operations, net of tax |
|
(137 |
) |
|
(256 |
) |
|
|
(41,901 |
) |
|
2,500 |
|
Net income |
|
17,881 |
|
|
60,605 |
|
|
|
30,833 |
|
|
106,719 |
|
Net loss (income) from continuing operations attributable to non-controlling interest |
|
554 |
|
|
71 |
|
|
|
(10,564 |
) |
|
12,825 |
|
Net income attributable to stockholders |
$ |
18,435 |
|
$ |
60,676 |
|
|
$ |
20,269 |
|
$ |
119,544 |
|
|
|
|
|
|
|
||||||||
Calculation of GAAP Earnings per Share |
|||||||||||||
|
|
|
|
|
|
||||||||
Numerator for basic and diluted earnings per share: |
|
|
|
|
|
||||||||
Net income from continuing operations attributable to stockholders |
$ |
18,572 |
|
$ |
60,932 |
|
|
$ |
62,170 |
|
$ |
117,044 |
|
Net (loss) income from discontinued operations attributable to stockholders |
|
(137 |
) |
|
(256 |
) |
|
|
(41,901 |
) |
|
2,500 |
|
Net income attributable to stockholders |
$ |
18,435 |
|
$ |
60,676 |
|
|
$ |
20,269 |
|
$ |
119,544 |
|
|
|
|
|
|
|
||||||||
Denominator for earnings per share: |
|
|
|
|
|
||||||||
Basic weighted average shares outstanding |
|
82,378 |
|
|
104,838 |
|
|
|
91,228 |
|
|
113,791 |
|
Effect of dilutive securities: |
|
|
|
|
|
||||||||
Restricted stock units |
|
886 |
|
|
758 |
|
|
|
607 |
|
|
553 |
|
Performance share awards |
|
327 |
|
|
— |
|
|
|
82 |
|
|
64 |
|
Diluted weighted average shares |
|
83,591 |
|
|
105,596 |
|
|
|
91,917 |
|
|
114,408 |
|
|
|
|
|
|
|
||||||||
Earnings per share attributable to stockholders: |
|
|
|
|
|
||||||||
Basic earnings per share from continuing operations |
$ |
0.22 |
|
$ |
0.58 |
|
|
$ |
0.68 |
|
$ |
1.03 |
|
Basic earnings (loss) per share from discontinued operations |
|
— |
|
|
— |
|
|
|
(0.46 |
) |
|
0.02 |
|
Basic earnings per share attributable to stockholders |
$ |
0.22 |
|
$ |
0.58 |
|
|
$ |
0.22 |
|
$ |
1.05 |
|
|
|
|
|
|
|
||||||||
Diluted earnings per share from continuing operations |
$ |
0.22 |
|
$ |
0.57 |
|
|
$ |
0.68 |
|
$ |
1.02 |
|
Diluted earnings (loss) per share from discontinued operations |
|
— |
|
|
— |
|
|
|
(0.46 |
) |
|
0.02 |
|
Diluted earnings per share attributable to stockholders |
$ |
0.22 |
|
$ |
0.57 |
|
|
$ |
0.22 |
|
$ |
1.04 |
|
Consolidated Balance Sheets |
||||||
(In thousands, except share data) |
||||||
|
|
|
||||
|
June 30, 2025 |
June 30, 2024 |
||||
Assets |
|
|
||||
Cash and cash equivalents |
$ |
83,725 |
|
$ |
125,146 |
|
Accounts receivable (net of |
|
99,092 |
|
|
100,965 |
|
Contract assets (net of |
|
318,337 |
|
|
335,831 |
|
Prepaid expenses and other current assets |
|
84,649 |
|
|
73,653 |
|
Current assets of discontinued operations |
|
— |
|
|
119,662 |
|
Total current assets |
|
585,803 |
|
|
755,257 |
|
Property and equipment (net of |
|
201,481 |
|
|
205,711 |
|
Intangible assets (net of |
|
250,770 |
|
|
269,259 |
|
Goodwill |
|
897,894 |
|
|
995,852 |
|
Deferred income tax assets |
|
762,859 |
|
|
773,002 |
|
Deferred compensation plan assets |
|
35,069 |
|
|
54,422 |
|
Investments in unconsolidated affiliates |
|
262,621 |
|
|
228,562 |
|
Operating lease right-of-use assets |
|
5,072 |
|
|
20,635 |
|
Other assets |
|
95,505 |
|
|
98,749 |
|
Total assets |
$ |
3,097,074 |
|
$ |
3,401,449 |
|
|
|
|
||||
Liabilities and stockholders' equity |
|
|||||
Accounts payable |
$ |
19,619 |
|
$ |
22,610 |
|
Accrued expenses |
|
59,151 |
|
|
58,482 |
|
Revenue share obligations |
|
347,306 |
|
|
292,792 |
|
Accrued compensation and benefits |
|
99,019 |
|
|
100,395 |
|
Deferred revenue |
|
22,548 |
|
|
19,642 |
|
Line of credit and current portion of long-term debt |
|
280,000 |
|
|
1,008 |
|
Current portion of notes payable to former limited partners |
|
— |
|
|
101,523 |
|
Current portion of liability related to the sale of future revenues |
|
49,712 |
|
|
51,798 |
|
Other current liabilities |
|
33,182 |
|
|
52,589 |
|
Current liabilities of discontinued operations |
|
96 |
|
|
45,724 |
|
Total current liabilities |
|
910,633 |
|
|
746,563 |
|
Liability related to the sale of future revenues, less current portion |
|
590,727 |
|
|
599,423 |
|
Deferred compensation plan obligations |
|
35,069 |
|
|
54,422 |
|
Operating lease liabilities, less current portion |
|
2,007 |
|
|
11,170 |
|
Other liabilities |
|
28,061 |
|
|
27,640 |
|
Total liabilities |
|
1,566,497 |
|
|
1,439,218 |
|
|
|
|
||||
Commitments and contingencies |
|
|
||||
Stockholders' equity: |
|
|
||||
Class A common stock, |
|
916 |
|
|
1,115 |
|
Treasury stock, at cost; 9,003,940 and 6,429,375 shares at June 30, 2025 and June 30, 2024, respectively |
|
(161,561 |
) |
|
(250,129 |
) |
Additional paid-in capital |
|
2,176,318 |
|
|
2,105,684 |
|
(Accumulated deficit) retained earnings |
|
(485,045 |
) |
|
105,590 |
|
Accumulated other comprehensive loss |
|
(51 |
) |
|
(29 |
) |
Total stockholders' equity |
|
1,530,577 |
|
|
1,962,231 |
|
Total liabilities and stockholders' equity |
$ |
3,097,074 |
|
$ |
3,401,449 |
|
Consolidated Statements of Cash Flows |
||||||
(In thousands) |
||||||
|
|
|
||||
|
Year Ended June 30, |
|||||
|
|
2025 |
|
|
2024 |
|
Operating activities |
|
|
||||
Net income |
$ |
30,833 |
|
$ |
106,719 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
||||
Net loss (income) from discontinued operations, net of tax |
|
41,901 |
|
|
(2,500 |
) |
Depreciation and amortization |
|
117,631 |
|
|
128,754 |
|
Equity in net (income) loss of unconsolidated affiliates |
|
(11,972 |
) |
|
295 |
|
Deferred income taxes |
|
27,076 |
|
|
(123,276 |
) |
Stock-based compensation |
|
23,154 |
|
|
23,290 |
|
Impairment of assets |
|
144,481 |
|
|
140,053 |
|
Other, net |
|
(23,036 |
) |
|
(4,518 |
) |
Changes in operating assets and liabilities, net of the effects of acquisitions: |
|
|
||||
Accounts receivable |
|
3,006 |
|
|
(15,622 |
) |
Contract assets |
|
17,557 |
|
|
(39,265 |
) |
Prepaid expenses and other assets |
|
17,481 |
|
|
237 |
|
Accounts payable |
|
(3,108 |
) |
|
(10,661 |
) |
Revenue share obligations |
|
54,514 |
|
|
30,504 |
|
Accrued expenses, deferred revenue, and other liabilities |
|
(21,709 |
) |
|
44,133 |
|
Net cash provided by operating activities from continuing operations |
|
417,809 |
|
|
278,143 |
|
Net cash (used in) provided by operating activities from discontinued operations |
|
(16,380 |
) |
|
18,417 |
|
Net cash provided by operating activities |
$ |
401,429 |
|
$ |
296,560 |
|
Investing activities |
|
|
||||
Purchases of property and equipment |
$ |
(82,649 |
) |
$ |
(81,189 |
) |
Proceeds from sale of assets |
|
20,402 |
|
|
— |
|
Acquisition of businesses, net of cash acquired |
|
(39,848 |
) |
|
— |
|
Sale of investment in unconsolidated affiliates |
|
— |
|
|
12,753 |
|
Other |
|
— |
|
|
(30 |
) |
Net cash used in investing activities |
$ |
(102,095 |
) |
$ |
(68,466 |
) |
Financing activities |
|
|
||||
Payments on notes payable |
$ |
(102,531 |
) |
$ |
(100,937 |
) |
Proceeds from credit facility |
|
435,000 |
|
|
— |
|
Payments on credit facility |
|
(155,000 |
) |
|
(215,000 |
) |
Proceeds from sale of future revenues |
|
42,325 |
|
|
681,427 |
|
Payments on liability related to the sale of future revenues |
|
(53,107 |
) |
|
(31,535 |
) |
Cash dividends paid |
|
(77,445 |
) |
|
(95,207 |
) |
Repurchase of Class A common stock |
|
(400,191 |
) |
|
(400,000 |
) |
Payments on deferred consideration related to acquisition of business |
|
— |
|
|
(27,187 |
) |
Payments on earn-out liabilities |
|
(22,700 |
) |
|
(1,375 |
) |
Other, net |
|
(7,084 |
) |
|
(2,906 |
) |
Net cash used in financing activities |
$ |
(340,733 |
) |
$ |
(192,720 |
) |
Effect of exchange rate changes on cash flows |
|
(22 |
) |
|
(21 |
) |
Net (decrease) increase in cash and cash equivalents |
|
(41,421 |
) |
|
35,353 |
|
Cash and cash equivalents at beginning of period |
|
125,146 |
|
|
89,793 |
|
Cash and cash equivalents at end of period |
$ |
83,725 |
|
$ |
125,146 |
|
Supplemental Financial Information |
||||||
Reconciliation of Net Cash Provided by Operating Activities from Continuing Operations to Free Cash Flow |
||||||
(Unaudited) |
||||||
(In thousands) |
||||||
|
|
|
||||
|
Year Ended June 30, |
|||||
|
|
2025 |
|
|
2024 |
|
Net cash provided by operating activities from continuing operations |
$ |
417,809 |
|
$ |
278,143 |
|
Early termination payments to certain former limited partners that elected to execute a Unit Exchange Agreement (a) |
|
(101,524 |
) |
|
(99,665 |
) |
Purchases of property and equipment |
|
(82,649 |
) |
|
(81,189 |
) |
Cash payments to OMNIA for the sale of future revenues (b) |
|
(53,107 |
) |
|
(31,535 |
) |
Cash tax payments on proceeds received from the sale of future revenues |
|
— |
|
|
162,292 |
|
Free cash flow |
$ |
180,529 |
|
$ |
228,046 |
|
| _________________________________ | |
(a) |
Early termination payments to certain former limited partners that elected to execute a Unit Exchange Agreement in connection with Premier's August 2020 restructuring are presented in the Consolidated Statements of Cash Flows under “Payments made on notes payable." During the year ended June 30, 2025, the company paid |
(b) |
Cash payments to OMNIA for the sale of future revenues in connection with our sale of non-healthcare contracts to OMNIA are presented in the Consolidated Statements of Cash Flows under "Payments on liability related to the sale of future revenues." During the year ended June 30, 2025, the company paid |
Supplemental Financial Information |
|||||||||||||
Reconciliation of Net Income from Continuing Operations to Adjusted EBITDA |
|||||||||||||
Reconciliation of Operating Income to Segment Adjusted EBITDA |
|||||||||||||
Reconciliation of Net Income Attributable to Stockholders to Adjusted Net Income |
|||||||||||||
(Unaudited) |
|||||||||||||
(In thousands) |
|||||||||||||
|
|
|
|
|
|
||||||||
|
Three Months Ended |
|
Year Ended |
||||||||||
|
June 30, |
|
June 30, |
||||||||||
|
|
2025 |
|
|
2024 |
|
|
|
2025 |
|
|
2024 |
|
Net income from continuing operations |
$ |
18,018 |
|
$ |
60,861 |
|
|
$ |
72,734 |
|
$ |
104,219 |
|
Interest expense, net |
|
6,305 |
|
|
73 |
|
|
|
17,223 |
|
|
662 |
|
Income tax expense |
|
7,083 |
|
|
25,723 |
|
|
|
25,315 |
|
|
42,302 |
|
Depreciation and amortization |
|
20,052 |
|
|
20,636 |
|
|
|
79,442 |
|
|
81,728 |
|
Amortization of purchased intangible assets |
|
9,499 |
|
|
9,794 |
|
|
|
38,189 |
|
|
47,026 |
|
EBITDA |
|
60,957 |
|
|
117,087 |
|
|
|
232,903 |
|
|
275,937 |
|
Stock-based compensation |
|
7,669 |
|
|
205 |
|
|
|
23,700 |
|
|
23,876 |
|
Acquisition- and disposition-related expenses |
|
2,520 |
|
|
4,117 |
|
|
|
6,943 |
|
|
12,612 |
|
Strategic initiative and restructuring-related expenses |
|
6,914 |
|
|
(119 |
) |
|
|
13,007 |
|
|
2,850 |
|
Operating income from revenues sold to OMNIA |
|
(16,840 |
) |
|
(15,624 |
) |
|
|
(62,469 |
) |
|
(55,283 |
) |
Equity in net (income) loss of unconsolidated affiliates |
|
(123 |
) |
|
(1,344 |
) |
|
|
(11,972 |
) |
|
295 |
|
Other non-operating gains |
|
(3,255 |
) |
|
— |
|
|
|
(79,826 |
) |
|
(11,046 |
) |
Impairment of assets |
|
10,810 |
|
|
— |
|
|
|
144,481 |
|
|
140,053 |
|
Other reconciling items, net |
|
204 |
|
|
(309 |
) |
|
|
(13,647 |
) |
|
(309 |
) |
Adjusted EBITDA |
$ |
68,856 |
|
$ |
104,013 |
|
|
$ |
253,120 |
|
$ |
388,985 |
|
Add: Loss from Contigo Health (a) |
|
2,252 |
|
|
2,032 |
|
|
|
7,315 |
|
|
7,206 |
|
Adjusted EBITDA excluding Contigo Health |
$ |
71,108 |
|
$ |
106,045 |
|
|
$ |
260,435 |
|
$ |
396,191 |
|
|
|
|
|
|
|
||||||||
(a) Contigo Health was in a loss position which results in an increase to adjusted EBITDA and adjusted EPS when excluding Contigo Health. |
|||||||||||||
|
|
|
|
|
|
||||||||
Income before income taxes |
$ |
25,101 |
|
$ |
86,584 |
|
|
$ |
98,049 |
|
$ |
146,521 |
|
Equity in net (income) loss of unconsolidated affiliates |
|
(123 |
) |
|
(1,344 |
) |
|
|
(11,972 |
) |
|
295 |
|
Interest expense, net |
|
6,305 |
|
|
73 |
|
|
|
17,223 |
|
|
662 |
|
Other income, net |
|
(6,419 |
) |
|
(2,332 |
) |
|
|
(102,184 |
) |
|
(20,832 |
) |
Operating income |
|
24,864 |
|
|
82,981 |
|
|
|
1,116 |
|
|
126,646 |
|
Depreciation and amortization |
|
20,052 |
|
|
20,636 |
|
|
|
79,442 |
|
|
81,728 |
|
Amortization of purchased intangible assets |
|
9,499 |
|
|
9,794 |
|
|
|
38,189 |
|
|
47,026 |
|
Stock-based compensation |
|
7,669 |
|
|
205 |
|
|
|
23,700 |
|
|
23,876 |
|
Acquisition- and disposition-related expenses |
|
2,520 |
|
|
4,117 |
|
|
|
6,943 |
|
|
12,612 |
|
Strategic initiative and restructuring-related expenses |
|
6,914 |
|
|
(119 |
) |
|
|
13,007 |
|
|
2,850 |
|
Operating income from revenues sold to OMNIA |
|
(16,840 |
) |
|
(15,624 |
) |
|
|
(62,469 |
) |
|
(55,283 |
) |
Deferred compensation plan expense |
|
3,165 |
|
|
1,400 |
|
|
|
4,603 |
|
|
8,769 |
|
Impairment of assets |
|
10,810 |
|
|
— |
|
|
|
144,481 |
|
|
140,053 |
|
Other reconciling items, net |
|
203 |
|
|
623 |
|
|
|
4,108 |
|
|
708 |
|
Adjusted EBITDA |
$ |
68,856 |
|
$ |
104,013 |
|
|
$ |
253,120 |
|
$ |
388,985 |
|
|
|
|
|
|
|
||||||||
SEGMENT ADJUSTED EBITDA |
|
|
|
|
|
||||||||
Supply Chain Services |
$ |
89,986 |
|
$ |
109,617 |
|
|
$ |
326,902 |
|
$ |
409,669 |
|
Performance Services |
|
17,170 |
|
|
32,820 |
|
|
|
60,692 |
|
|
113,845 |
|
Corporate |
|
(38,300 |
) |
|
(38,424 |
) |
|
|
(134,474 |
) |
|
(134,529 |
) |
Adjusted EBITDA |
$ |
68,856 |
|
$ |
104,013 |
|
|
$ |
253,120 |
|
$ |
388,985 |
|
|
|
|
|
|
|
||||||||
Net income attributable to stockholders |
$ |
18,435 |
|
$ |
60,676 |
|
|
$ |
20,269 |
|
$ |
119,544 |
|
Net loss (income) from discontinued operations, net of tax |
|
137 |
|
|
256 |
|
|
|
41,901 |
|
|
(2,500 |
) |
Income tax expense |
|
7,083 |
|
|
25,723 |
|
|
|
25,315 |
|
|
42,302 |
|
Amortization of purchased intangible assets |
|
9,499 |
|
|
9,794 |
|
|
|
38,189 |
|
|
47,026 |
|
Stock-based compensation |
|
7,669 |
|
|
205 |
|
|
|
23,700 |
|
|
23,876 |
|
Acquisition- and disposition-related expenses |
|
2,520 |
|
|
4,117 |
|
|
|
6,943 |
|
|
12,612 |
|
Strategic initiative and restructuring-related expenses |
|
6,914 |
|
|
(119 |
) |
|
|
13,007 |
|
|
2,850 |
|
Operating income from revenues sold to OMNIA |
|
(16,840 |
) |
|
(15,624 |
) |
|
|
(62,469 |
) |
|
(55,283 |
) |
Equity in net (income) loss of unconsolidated affiliates |
|
(123 |
) |
|
(1,344 |
) |
|
|
(11,972 |
) |
|
295 |
|
Other non-operating gains |
|
(3,255 |
) |
|
— |
|
|
|
(79,826 |
) |
|
(11,046 |
) |
Impairment of assets |
|
10,810 |
|
|
— |
|
|
|
144,481 |
|
|
140,053 |
|
Other reconciling items, net |
|
4,181 |
|
|
4,647 |
|
|
|
16,451 |
|
|
6,087 |
|
Adjusted income before income taxes |
|
47,030 |
|
|
88,331 |
|
|
|
175,989 |
|
|
325,816 |
|
Income tax expense on adjusted income before income taxes |
|
11,287 |
|
|
23,849 |
|
|
|
42,237 |
|
|
87,970 |
|
Adjusted net income |
$ |
35,743 |
|
$ |
64,482 |
|
|
$ |
133,752 |
|
$ |
237,846 |
|
Supplemental Financial Information |
|||||||||||||
Reconciliation of GAAP EPS to Adjusted EPS |
|||||||||||||
(Unaudited) |
|||||||||||||
(In thousands, except per share data) |
|||||||||||||
|
|
|
|
|
|
||||||||
|
Three Months Ended |
|
Year Ended |
||||||||||
|
June 30, |
|
June 30, |
||||||||||
|
|
2025 |
|
|
2024 |
|
|
|
2025 |
|
|
2024 |
|
Net income attributable to stockholders |
$ |
18,435 |
|
$ |
60,676 |
|
|
$ |
20,269 |
|
$ |
119,544 |
|
Net loss (income) from discontinued operations, net of tax |
|
137 |
|
|
256 |
|
|
|
41,901 |
|
|
(2,500 |
) |
Income tax expense |
|
7,083 |
|
|
25,723 |
|
|
|
25,315 |
|
|
42,302 |
|
Amortization of purchased intangible assets |
|
9,499 |
|
|
9,794 |
|
|
|
38,189 |
|
|
47,026 |
|
Stock-based compensation |
|
7,669 |
|
|
205 |
|
|
|
23,700 |
|
|
23,876 |
|
Acquisition- and disposition-related expenses |
|
2,520 |
|
|
4,117 |
|
|
|
6,943 |
|
|
12,612 |
|
Strategic initiative and restructuring-related expenses |
|
6,914 |
|
|
(119 |
) |
|
|
13,007 |
|
|
2,850 |
|
Operating income from revenues sold to OMNIA |
|
(16,840 |
) |
|
(15,624 |
) |
|
|
(62,469 |
) |
|
(55,283 |
) |
Equity in net (income) loss of unconsolidated affiliates |
|
(123 |
) |
|
(1,344 |
) |
|
|
(11,972 |
) |
|
295 |
|
Other non-operating gains |
|
(3,255 |
) |
|
— |
|
|
|
(79,826 |
) |
|
(11,046 |
) |
Impairment of assets |
|
10,810 |
|
|
— |
|
|
|
144,481 |
|
|
140,053 |
|
Other reconciling items, net |
|
4,181 |
|
|
4,647 |
|
|
|
16,451 |
|
|
6,087 |
|
Adjusted income before income taxes |
|
47,030 |
|
|
88,331 |
|
|
|
175,989 |
|
|
325,816 |
|
Income tax expense on adjusted income before income taxes |
|
11,287 |
|
|
23,849 |
|
|
|
42,237 |
|
|
87,970 |
|
Adjusted net income |
$ |
35,743 |
|
$ |
64,482 |
|
|
$ |
133,752 |
|
$ |
237,846 |
|
|
|
|
|
|
|
||||||||
Weighted average: |
|
|
|
|
|
||||||||
Basic weighted average shares outstanding |
|
82,378 |
|
|
104,838 |
|
|
|
91,228 |
|
|
113,791 |
|
Dilutive shares |
|
1,213 |
|
|
758 |
|
|
|
689 |
|
|
617 |
|
Weighted average shares outstanding - diluted |
|
83,591 |
|
|
105,596 |
|
|
|
91,917 |
|
|
114,408 |
|
|
|
|
|
|
|
||||||||
Basic earnings per share attributable to stockholders |
$ |
0.22 |
|
$ |
0.58 |
|
|
$ |
0.22 |
|
$ |
1.05 |
|
Net loss (income) from discontinued operations, net of tax |
|
— |
|
|
— |
|
|
|
0.46 |
|
|
(0.02 |
) |
Income tax expense |
|
0.09 |
|
|
0.25 |
|
|
|
0.28 |
|
|
0.37 |
|
Amortization of purchased intangible assets |
|
0.12 |
|
|
0.09 |
|
|
|
0.42 |
|
|
0.41 |
|
Stock-based compensation |
|
0.09 |
|
|
— |
|
|
|
0.26 |
|
|
0.21 |
|
Acquisition- and disposition-related expenses |
|
0.03 |
|
|
0.04 |
|
|
|
0.08 |
|
|
0.11 |
|
Strategic initiative and restructuring-related expenses |
|
0.08 |
|
|
— |
|
|
|
0.14 |
|
|
0.03 |
|
Operating income from revenues sold to OMNIA |
|
(0.20 |
) |
|
(0.15 |
) |
|
|
(0.68 |
) |
|
(0.49 |
) |
Equity in net (income) loss of unconsolidated affiliates |
|
— |
|
|
(0.01 |
) |
|
|
(0.13 |
) |
|
— |
|
Other non-operating gains |
|
(0.04 |
) |
|
— |
|
|
|
(0.88 |
) |
|
(0.10 |
) |
Impairment of assets |
|
0.13 |
|
|
— |
|
|
|
1.58 |
|
|
1.23 |
|
Other reconciling items, net |
|
0.06 |
|
|
0.04 |
|
|
|
0.18 |
|
|
0.05 |
|
Impact of corporation taxes |
|
(0.14 |
) |
|
(0.23 |
) |
|
|
(0.46 |
) |
|
(0.77 |
) |
Impact of dilutive shares |
|
(0.01 |
) |
|
— |
|
|
|
(0.01 |
) |
|
— |
|
Adjusted earnings per share |
$ |
0.43 |
|
$ |
0.61 |
|
|
$ |
1.46 |
|
$ |
2.08 |
|
Add: Loss from Contigo Health (a) |
|
0.03 |
|
|
0.03 |
|
|
|
0.08 |
|
|
0.09 |
|
Adjusted earnings per share excluding Contigo Health |
$ |
0.46 |
|
$ |
0.64 |
|
|
$ |
1.54 |
|
$ |
2.17 |
|
| _________________________________ | |
(a) |
Contigo Health was in a loss position which results in an increase to adjusted EBITDA and adjusted EPS when excluding Contigo Health. |
Supplemental Financial Information |
|||||||||||||
Reconciliation of Certain Financial Measures to Adjust for Contigo Health |
|||||||||||||
(Unaudited) |
|||||||||||||
(In thousands) |
|||||||||||||
|
|
|
|
|
|
||||||||
|
Three Months Ended |
|
Year Ended |
||||||||||
|
June 30, |
|
June 30, |
||||||||||
|
|
2025 |
|
|
2024 |
|
|
|
2025 |
|
|
2024 |
|
Net revenue |
$ |
262,857 |
|
$ |
300,246 |
|
|
$ |
1,012,647 |
|
$ |
1,136,009 |
|
Less: Contigo Health |
|
(4,885 |
) |
|
(8,585 |
) |
|
|
(26,694 |
) |
|
(39,846 |
) |
Net revenue excluding Contigo Health |
$ |
257,972 |
|
$ |
291,661 |
|
|
$ |
985,953 |
|
$ |
1,096,163 |
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA |
$ |
68,856 |
|
$ |
104,013 |
|
|
$ |
253,120 |
|
$ |
388,985 |
|
Add: Loss from Contigo Health (a) |
|
2,252 |
|
|
2,032 |
|
|
|
7,315 |
|
|
7,206 |
|
Adjusted EBITDA excluding Contigo Health |
$ |
71,108 |
|
$ |
106,045 |
|
|
$ |
260,435 |
|
$ |
396,191 |
|
|
|
|
|
|
|
||||||||
Adjusted EPS |
$ |
0.43 |
|
$ |
0.61 |
|
|
$ |
1.46 |
|
$ |
2.08 |
|
Add: Loss from Contigo Health (a) |
|
0.03 |
|
|
0.03 |
|
|
|
0.08 |
|
|
0.09 |
|
Adjusted EPS excluding Contigo Health |
$ |
0.46 |
|
$ |
0.64 |
|
|
$ |
1.54 |
|
$ |
2.17 |
|
| _________________________________ | |
(a) |
Contigo Health was in a loss position which results in an increase to adjusted EBITDA and adjusted EPS when excluding Contigo Health. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250819934448/en/
Investor contact:
Ben Krasinski
Senior Director, Investor Relations
704.816.5644
ben_krasinski@premierinc.com
Media contact:
Amanda Forster
Vice President, Integrated Communications
202.879.8004
amanda_forster@premierinc.com
Source: Premier, Inc.
